Table 2.

Clinical trials on differentiation phenotypes of infused T cells and anti-cancer therapy.

Publication year	Cancer	No. of Patients	T-cell therapy type	Antigen	Construct design	Transduction methods	Manufacture	Transfer dose	Objective response	Registration No.	Reference
2009	Melanoma	36	TCR-T	DMF5	DMF5 TCRα-T2A-DMF5 TCRβ	Retroviral vector	Stimulated with OKT3 (50 ng/mL) and IL2 (300 IU/mL) for 2 days, transduced and expanded with IL2 (6000 IU/mL) for 7-10 days, stimulated and expanded with OKT3, irradiated PBL and IL2 (6000 IU/mL) for 9-14 days	1.5-107×109	1 CR, 8 PR, 27 NR	NCI-07-C-0174, NCI-07-C-0175	(6)
2011	Neuroblastoma	19	CAR-CTL	GD2	GD2-specific 14g2a.ζ CAR	Retroviral vector	Stimulated with OKT3 and IL2 (100 U/mL) for 2 days, transduced, expanded with IL2 (50 U/mL) for 9-15 days	2×107, 5×107 or 1×108 cells/m2	3 CR, 8 NED, 1 PR, 1 SD, 4 PD, 2 tumor necrosis	NCT00085930	(7)
2011	Melanoma	93	TIL	N/A	N/A	N/A	Grown from resected metastatic melanoma lesions with IL-2 (6000 IU/mL)	Less than 3×1010 to more than 9×1010	20 CR, 32 PR, 41 NR	None	(9)
2018	Biliary tract cancer	17	CAR-T	EGFR	EGFR-specific CD137-CD3ζ-CAR	Lentiviral vector	Stimulated with OKT3 (50 ng/mL) and IL2 (500 U/mL) for 2 days, transduced, expanded for 10 days	0.8-4.1×106/kg, 1-3 cycles within 6 months	1 CR, 10 SD, 6 PD	NCT01869166	(10)
2018	Chronic lymphocytic leukemia	38	CAR-T	CD19	CD19-specific CAR with 4–1BB/CD3ζ domains	Lentiviral vector	Stimulated by anti-CD3/28 beads, transduced, expanded for 9-11 days	0.2-7×106/kg interquartile	8 CR, 5 PR (3 PRTD), 25 NR	NCT01029366, NCT01747486, NCT02640209	(5)
2019	Multiple myeloma	25	CAR-T	BCMA	anti-BCMA scFv-4-1BB-CD3ζ CAR	Lentiviral vector	Stimulated by anti-CD3/28 beads, transduced, expanded with IL2 for 10-12 days	1-5×107 or 1-5×108	1 stringent CR, 1 CR, 5 very good PR, 5 PR, 5 minimal response, 6 SD, 2 PD	NCT02546167	(8)
2020	Pancreatic carcinoma	14	CAR-T	EGFR	anti-EGFR scFv-CD137-CD3ζ CAR	Lentiviral vector	Stimulated with OKT3 (50 ng/mL) and IL2 (500 U/mL) for 2 days, transduced, expanded for 10 days	1.31-8.9×106/kg, 1-3 cycles within 6 months	4 PR, 8 SD, 2 PD	NCT01869166	(11)
2020	Melanoma	38	TIL	N/A	N/A	N/A	Initially cultured from enzymatic tumor digests and tumor fragments, generated by rapid expansion with irradiated PBMC, anti-CD3 antibody (30 ng/mL), and IL-2 (3000 IU/mL) for 14 days	a single infusion of unselected 1.1×108-1×1011	17 CR, 21 NR	NCT00001832, NCT00513604, NCT01319565, NCT01468818, NCT01585415, NCT01993719	(100)
2020	LBCL	24	CAR-T	CD19	anti-CD19 scFv-CD28-CD3ζ CAR	Retroviral vector	Stimulated with anti-CD3 antibody and IL-2, transduced, and expanded	2 × 106 CAR-positive cells/kg	9 CR, 1PR, 13 PD, 1 NE	None	(101)